Literature DB >> 20222791

Preclinical assessment of fibroblast activation protein as a target for antitumor therapy.

Simon W Hayward1.   

Abstract

Year:  2010        PMID： 20222791     DOI： 10.2217/fon.10.8

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


× No keyword cloud information.
  4 in total

Review 1.  Intestinal myofibroblasts: targets for stem cell therapy.

Authors:  R C Mifflin; I V Pinchuk; J I Saada; D W Powell
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-01-20       Impact factor: 4.052

2.  Targeting inhibition of fibroblast activation protein-α and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Tamyra D Downs; Patrick A McKee
Journal:  Neoplasia       Date:  2013-04       Impact factor: 5.715

3.  Suppression of tumor growth in mice by rationally designed pseudopeptide inhibitors of fibroblast activation protein and prolyl oligopeptidase.

Authors:  Kenneth W Jackson; Victoria J Christiansen; Vivek R Yadav; Robert Silasi-Mansat; Florea Lupu; Vibhudutta Awasthi; Roy R Zhang; Patrick A McKee
Journal:  Neoplasia       Date:  2015-01       Impact factor: 5.715

4.  Impact of fibroblast activation protein on osteosarcoma cell lines in vitro.

Authors:  Lixiang Ding; Lin Ye; Jianli Xu; Wen G Jiang
Journal:  Oncol Lett       Date:  2014-01-10       Impact factor: 2.967
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.